Half-Life 3 remains as one of the most anticipated projects in gaming, and a number of solid rumors have recently surfaced ...

Eventually, I got everything together, played through Alyx, and had a great time. But, as rumors swirl that the announcement ...

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small ...

A few of the users, like @David75605212, shared an optimistic approach and exclaimed that Half-Life 3 seems to be confirmed. The community is creating new theories and trying to string together ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of ...

MBX Biosciences reports Phase 1 trial results for MBX 1416, a GLP-1 receptor antagonist for post-bariatric hypoglycemia. Phase 2 starts in 2025.

Hey, you! Don't just stand there half-naked with your stomach growling. Grab a stick, pick up a rock, craft a rope from ...

MBX Biosciences (MBX) announced positive results from its Phase 1 single ascending dose, SAD, and multiple ascending dose, MAD, clinical trial ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin ...

Fluoride exposure appears to slightly decrease IQ scores in children, a new federal meta-analysis has concluded -- but not at ...

Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage ...